

GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS



BIO009F
August 2014

Shalini Shahani Dewan
Project Analyst

ISBN: 1-56965-902-8



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
BIOSYNTHESIS OF PROTEINS	10
TRANSCRIPTION	10
TRANSLATION	11
POST-TRANSCRIPTIONAL MODIFICATIONS	11
HISTORY OF BIOENGINEERED PROTEIN DRUGS	11
<i>TABLE 1 EVOLUTION OF BIOENGINEERED PROTEINS DRUGS</i>	11
BIOENGINEERED PROTEIN DRUGS	12
<i>TABLE 2 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS</i>	13
ADVANTAGES OF BIOENGINEERED PROTEIN DRUGS	14
MANUFACTURING TECHNOLOGY	14
Fractionation or Cohn Process	14
<i>TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION</i>	15
Microbial Cell Fermentation and Bioreactors	16
<i>TABLE 4 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION</i>	16
Genetic Engineering	17
Genetically Modified Organisms	17
Pharming	17
<i>TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICRO-ORGANISMS</i>	17
Mammalian Cell Culture	18
<i>TABLE 6 PROTEIN DRUGS MADE BY CELL CULTURE</i>	19
Cell-Free Protein Synthesis Systems	19
ADMINISTRATION TECHNOLOGIES OF BIOENGINEERED PROTEIN DRUGS	19
Traditional Methods of Drug Delivery	20
Oral	20
Topical	20
Transmucosal	20

TOPIC	PAGE NO.
Inhalation	20
Parenteral	20
<i>TABLE 7 ROUTES OF DRUG DELIVERY</i>	20
Limitations Encountered by Traditional Drug Delivery	21
Current Research and Novel Approaches	21
Targeted Drug Delivery Carriers	21
Micelles	22
Liposomes	22
Microspheres	22
Nanoparticles	22
Microemulsions	22
Hydrogels	23
Thin-film Drug Delivery	23
Prodrug	23
MOLECULAR CLASSIFICATION OF PROTEIN DRUGS	23
Monoclonal Antibodies	23
Cytokines	24
Interferons	25
Interleukins	25
Colony Stimulating Factors	25
Peptide Hormones	26
Follicle Stimulating Hormones and Luteinizing Hormones	26
Growth Hormones	26
Erythropoietin	26
Insulin	27
Vaccines	27
Live Attenuated Vaccines	27
Inactivated/Killed Vaccines	28
Toxoid	28
Subunit/Conjugate	28
Therapeutic Enzymes	28
Digestive Enzymes	29
Metabolic Enzymes	29
Other Enzymes	29
Peptide Antibiotics	30
Blood Products	30
Alpha 1-Protease Inhibitor	30
Antihemophilic Factor	31
Antithrombin	31
C1 Esterase Inhibitor	31
Coagulation Factors	31
Immune Globulins	32
Protein C	32
Thrombin	32
CHAPTER 4 REGULATORY ASPECTS	34
MONOCLONAL ANTIBODIES	34

TOPIC	PAGE NO.
<i>TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2009-MAY 2014</i>	34
CYTOKINES	36
<i>TABLE 9 NEW APPROVALS OF CYTOKINES, 2009-MAY 2014</i>	36
VACCINES	37
<i>TABLE 10 NEW APPROVALS IN VACCINES, 2009-MAY 2014</i>	37
PEPTIDE HORMONES	39
<i>TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES, 2009-MAY 2014</i>	40
THERAPEUTIC ENZYMES	40
<i>TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2009-MAY 2014</i>	40
BLOOD PRODUCTS	41
<i>TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS, 2009-MAY 2014</i>	41
RECALLS	42
<i>TABLE 14 RECALLS, FROM 2009 TO MAY 2014</i>	42
NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS	45
<i>TABLE 15 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS, FROM 2009 TO MAY 2014</i>	45
SAFETY ALERTS	48
<i>TABLE 16 SAFETY ALERTS, FROM 2009 TO MAY 2014</i>	48
CHAPTER 5 NEW DEVELOPMENTS	52
VACCINES	52
<i>TABLE 17 PIPELINE PRODUCTS IN VACCINES</i>	53
PEPTIDE HORMONES	57
<i>TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES</i>	57
THERAPEUTIC ENZYMES	59
<i>TABLE 19 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES</i>	59
BLOOD PRODUCTS	59
<i>TABLE 20 PIPELINE PRODUCTS IN BLOOD PRODUCTS</i>	60
PEPTIDE ANTIBIOTICS	61
<i>TABLE 21 PIPELINE PRODUCTS OF PEPTIDE ANTIBIOTICS</i>	61
CYTOKINES	62
<i>TABLE 22 PIPELINE PRODUCTS OF CYTOKINES</i>	63
MONOCLONAL ANTIBODIES	65
<i>TABLE 23 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES</i>	66
MERGERS AND ACQUISITIONS	73
<i>TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES, 2009 TO FEBRUARY 2014</i>	73
NEW TECHNOLOGIES	78
INNOVATIONS IN BIOLOGIC DRUGS	78
FUSION PROTEIN	79
NANOMEDICINE	79
ENGINEERED PROTEIN SCAFFOLDS	79
PROGRAMMED BIOMANUFACTURING	80
CHAPTER 6 MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS	82
MARKET BY TYPE	83
GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET	83

TOPIC	PAGE NO.
<i>TABLE 25 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	83
<i>FIGURE 1 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2012-2019 (\$ MILLIONS)</i>	84
PEPTIDE HORMONES	84
Market Overview	85
Market Revenue	86
<i>TABLE 26 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
<i>FIGURE 2 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2012-2019 (\$ MILLIONS)</i>	87
VACCINES	87
Market Overview	88
Market Revenue	89
<i>TABLE 27 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	90
<i>FIGURE 3 GLOBAL MARKET FOR VACCINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	90
THERAPEUTIC ENZYMES	90
Market Overview	91
Market Revenue	92
<i>TABLE 28 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	92
<i>FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2012-2019 (\$ MILLIONS)</i>	92
MONOCLONAL ANTIBODIES	93
Market Overview	93
Market Revenue	94
<i>TABLE 29 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	95
<i>FIGURE 5 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)</i>	95
CYTOKINES	96
Market Overview	96
Market Revenue	97
<i>TABLE 30 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	98
<i>FIGURE 6 GLOBAL MARKET FOR CYTOKINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	98
BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS	99
Market Overview	100
Market Revenue	101
<i>TABLE 31 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	102
<i>FIGURE 7 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, 2012-2019 (\$ MILLIONS)</i>	102
MARKET SHARE	102
<i>TABLE 32 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)</i>	103
<i>FIGURE 8 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)</i>	103
MARKET BY REGION	103

TOPIC	PAGE NO.
MARKET OVERVIEW	104
MARKET REVENUE	106
<i>TABLE 33 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	106
<i>FIGURE 9 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)</i>	107
MARKET SHARE	107
<i>TABLE 34 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)</i>	107
<i>FIGURE 10 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)</i>	107
CHAPTER 7 MARKET BY DISEASES OF BIOENGINEERED PROTEIN DRUGS	110
MARKET BY DISEASES	110
GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET BY DISEASES	110
<i>TABLE 35 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2019 (\$ MILLIONS)</i>	111
<i>FIGURE 11 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2012-2019 (\$ MILLIONS)</i>	111
DIABETES	112
Type 1 Diabetes	112
Type 2 Diabetes	112
Gestational Diabetes	112
Market Overview	113
Market Revenue	114
<i>TABLE 36 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	114
<i>FIGURE 12 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2012-2019 (\$ MILLIONS)</i>	114
Market Share	115
<i>TABLE 37 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)</i>	115
<i>FIGURE 13 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)</i>	115
CANCER	116
<i>TABLE 38 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN</i>	116
<i>TABLE 39 CATEGORIES OF CANCER</i>	117
Market Overview	118
Market Revenue	119
<i>TABLE 40 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	120
<i>FIGURE 14 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2012-2019 (\$ MILLIONS)</i>	120
Market Share	120
<i>TABLE 41 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)</i>	121
<i>FIGURE 15 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)</i>	121
BLOOD DISORDERS AND SKIN DISEASES	121
Blood Disorders	121

TOPIC	PAGE NO.
Bleeding Disorders	122
Anemia	123
Leukemia	124
Multiple Myeloma	124
Skin Diseases	124
Skin and Skin structure Infections (SSSI)	125
Complicated Skin and Skin Structure Infection (cSSSI)	125
Uncomplicated Skin and Skin Structure Infection (uSSSI)	125
Clostridium difficile (C.difficile)	126
Market Overview	126
Market Revenue	127
<i>TABLE 42 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	128
<i>FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2012-2019 (\$ MILLIONS)</i>	128
Market Share	128
<i>TABLE 43 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)</i>	129
<i>FIGURE 17 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)</i>	129
GROWTH HORMONE DISORDER, ENZYME DISORDER AND FERTILITY DISORDER	129
Market Overview	130
Market Revenue	131
<i>TABLE 44 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	132
<i>FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2012-2019 (\$ MILLIONS)</i>	132
Market Share	132
<i>TABLE 45 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)</i>	133
<i>FIGURE 19 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)</i>	133
OTHERS	133
Rheumatoid Arthritis	134
Multiple Sclerosis	134
Crohn's Disease	134
Hepatitis	134
Influenza	135
Pneumonia	135
Cystic Fibrosis	136
Meningitis	136
Asthma	136
Market Overview	137
Market Revenue	137

TOPIC	PAGE NO.
<i>TABLE 46 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	138
<i>FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2012-2019 (\$ MILLIONS)</i>	138
Market Share	139
<i>TABLE 47 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)</i>	139
<i>FIGURE 21 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)</i>	139
CHAPTER 8 INDUSTRY STRUCTURE OF BIOENGINEERED PROTEIN DRUGS	142
INDUSTRY STRUCTURE OF BIOENGINEERED PROTEIN DRUGS, 2013	142
MONOCLONAL ANTIBODIES	142
<i>TABLE 48 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013</i>	142
Market Share	143
<i>TABLE 49 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)</i>	143
<i>FIGURE 22 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)</i>	144
PEPTIDE HORMONES	144
<i>TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013</i>	144
Market Share	146
<i>TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)</i>	146
<i>FIGURE 23 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)</i>	146
CYTOKINES	147
<i>TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2013</i>	147
Market Share	148
<i>TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)</i>	148
<i>FIGURE 24 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)</i>	148
THERAPEUTIC ENZYMES	149
<i>TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013</i>	149
Market Share	149
<i>TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)</i>	150
<i>FIGURE 25 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)</i>	150
VACCINES	150
<i>TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2013</i>	151
Market Share	153
<i>TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)</i>	154
<i>FIGURE 26 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)</i>	154
BLOOD PRODUCTS	154
<i>TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013</i>	155

TOPIC	PAGE NO.
Market Share	155
<i>TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)</i>	155
<i>FIGURE 27 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)</i>	156
PEPTIDE ANTIBIOTICS	156
<i>TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013</i>	156
Market Share	157
<i>TABLE 61 MARKET SHARE OF MANUFACTURERS/ SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)</i>	157
<i>FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)</i>	157
CHAPTER 9 PATENT ANALYSIS	160
PATENTS BY YEAR	160
<i>TABLE 62 NUMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	160
<i>FIGURE 29 UMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (%)</i>	161
PATENTS BY TYPE/ CATEGORY	161
<i>TABLE 63 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	161
<i>FIGURE 30 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	161
PATENTS BY COMPANY	162
<i>TABLE 64 NUMBER OF PATENTS, BY COMPANY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	162
PATENTS BY COUNTRY	169
<i>TABLE 65 NUMBER OF PATENTS, BY COUNTRY, JANUARY 2009 -FEBRUARY 2014 (NUMBER OF PATENTS)</i>	169
<i>TABLE 66 PATENT SHARES, BY COUNTRY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS/%)</i>	170
PATENTS BY ASSIGNEE	171
<i>TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	171
<i>FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)</i>	171
CHAPTER 10 THE CURRENT SITUATION	174
FACTORS AFFECTING BIOENGINEERED PROTEIN DRUGS	174
INCREASING PREVALENCE OF CHRONIC DISEASES	174
GROWING AGING POPULATION	174
LIFESTYLE CHANGES	175
NEW PRODUCT LAUNCHES	175
ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES	175
PRICE CONTROLS	176
REGULATORY PRESSURES	176
ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS	176
LICENSING AGREEMENTS	177
MERGERS AND ACQUISITIONS	178

TOPIC	PAGE NO.
CHAPTER 11 COMPANY PROFILES	180
ABBOTT LABORATORIES	180
ACTAVIS INC. (FORMERLY WATSON LABS)	180
ALEXION PHARMACEUTICALS	181
ALLERGAN INC.	181
AMGEN	182
BAXTER HEALTHCARE	182
BAYER HEALTHCARE PHARMACEUTICALS	183
BIOGEN IDEC INC.	183
BIOMARIN PHARMACEUTICAL INC.	184
BRISTOL-MYERS SQUIBB CO.	184
CSL LIMITED	185
ELI LILLY AND CO.	185
FRESENIUS KABI USA	186
GLAXOSMITHKLINE	187
HOFFMAN-LA-ROCHE	187
HOSPIRA	188
JOHNSON & JOHNSON	188
LUNDBECK LLC	189
MEDIMMUNE LLC	189
MERCK & CO. INC.	190
MERCK KGAA	191
MYLAN INC.	191
NOVARTIS	192
NOVO NORDISK INC.	192
PFIZER INC.	193
SANDOZ	194
SANOFI	194
SEATTLE GENETICS INC.	195
TAKEDA PHARMACEUTICAL U.S.A. INC.	196
UCB COMPANY	196
VIROPHARMA INC.	196
VERTEX PHARMACEUTICALS	197
WOCKHARDT LTD.	197
X-GEN PHARMACEUTICALS INC.	198
ZYMOGENETICS INC.	198
CHAPTER 12 APPENDIX—ABBREVIATIONS	200

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	8
TABLE 1 EVOLUTION OF BIOENGINEERED PROTEINS DRUGS	11
TABLE 2 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS	13
TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION	15
TABLE 4 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION	16
TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICRO-ORGANISMS	17
TABLE 6 PROTEIN DRUGS MADE BY CELL CULTURE	19
TABLE 7 ROUTES OF DRUG DELIVERY	20
TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2009-MAY 2014	34
TABLE 9 NEW APPROVALS OF CYTOKINES, 2009-MAY 2014	36
TABLE 10 NEW APPROVALS IN VACCINES, 2009-MAY 2014	37
TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES, 2009-MAY 2014	40
TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2009-MAY 2014	40
TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS, 2009-MAY 2014	41
TABLE 14 RECALLS, FROM 2009 TO MAY 2014	42
TABLE 15 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS, FROM 2009 TO MAY 2014	45
TABLE 16 SAFETY ALERTS, FROM 2009 TO MAY 2014	48
TABLE 17 PIPELINE PRODUCTS IN VACCINES	53
TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES	57
TABLE 19 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES	59
TABLE 20 PIPELINE PRODUCTS IN BLOOD PRODUCTS	60
TABLE 21 PIPELINE PRODUCTS OF PEPTIDE ANTIBIOTICS	61
TABLE 22 PIPELINE PRODUCTS OF CYTOKINES	63
TABLE 23 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES	66
TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES, 2009 TO FEBRUARY 2014	73
TABLE 25 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2019 (\$ MILLIONS)	83
TABLE 26 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 27 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	90
TABLE 28 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2019 (\$ MILLIONS)	92
TABLE 29 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 (\$ MILLIONS)	95
TABLE 30 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2019 (\$ MILLIONS)	98
TABLE 31 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2019 (\$ MILLIONS)	102
TABLE 32 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)	103
TABLE 33 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 (\$ MILLIONS)	106
TABLE 34 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)	107
TABLE 35 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2019 (\$ MILLIONS)	111

TABLE HEADING	PAGE NO.
TABLE 36 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, THROUGH 2019 (\$ MILLIONS)	114
TABLE 37 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)	115
TABLE 38 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN	116
TABLE 39 CATEGORIES OF CANCER	117
TABLE 40 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, THROUGH 2019 (\$ MILLIONS)	120
TABLE 41 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)	121
TABLE 42 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2019 (\$ MILLIONS)	128
TABLE 43 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)	129
TABLE 44 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2019 (\$ MILLIONS)	132
TABLE 45 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)	133
TABLE 46 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, THROUGH 2019 (\$ MILLIONS)	138
TABLE 47 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)	139
TABLE 48 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013	142
TABLE 49 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)	143
TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013	144
TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)	146
TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2013	147
TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)	148
TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013	149
TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)	150
TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2013	151
TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)	154
TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013	155
TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)	155
TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013	156
TABLE 61 MARKET SHARE OF MANUFACTURERS/ SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)	157
TABLE 62 NUMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	160
TABLE 63 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	161
TABLE 64 NUMBER OF PATENTS, BY COMPANY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	162

TABLE HEADING	PAGE NO.
TABLE 65 NUMBER OF PATENTS, BY COUNTRY, JANUARY 2009 -FEBRUARY 2014 (NUMBER OF PATENTS)	169
TABLE 66 PATENT SHARES, BY COUNTRY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS/%)	170
TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	171

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	8
FIGURE 1 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2012-2019 (\$ MILLIONS)	84
FIGURE 2 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2012-2019 (\$ MILLIONS)	87
FIGURE 3 GLOBAL MARKET FOR VACCINES BY REGION, 2012-2019 (\$ MILLIONS)	90
FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2012-2019 (\$ MILLIONS)	92
FIGURE 5 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2012-2019 (\$ MILLIONS)	95
FIGURE 6 GLOBAL MARKET FOR CYTOKINES BY REGION, 2012-2019 (\$ MILLIONS)	98
FIGURE 7 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, 2012-2019 (\$ MILLIONS)	102
FIGURE 8 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)	103
FIGURE 9 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 (\$ MILLIONS)	107
FIGURE 10 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)	107
FIGURE 11 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2012-2019 (\$ MILLIONS)	111
FIGURE 12 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2012-2019 (\$ MILLIONS)	114
FIGURE 13 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)	115
FIGURE 14 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2012-2019 (\$ MILLIONS)	120
FIGURE 15 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)	121
FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2012-2019 (\$ MILLIONS)	128
FIGURE 17 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)	129
FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2012-2019 (\$ MILLIONS)	132
FIGURE 19 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)	133
FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2012-2019 (\$ MILLIONS)	138
FIGURE 21 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)	139
FIGURE 22 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)	144
FIGURE 23 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)	146
FIGURE 24 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)	148
FIGURE 25 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)	150
FIGURE 26 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)	154

FIGURE TITLE	PAGE NO.
FIGURE 27 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)	156
FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)	157
FIGURE 29 NUMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (%)	161
FIGURE 30 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	161
FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)	171